--- title: "Alzamend Neuro issues 300,000 shares on conversion of Series B preferred stock" url: "https://aibio.space/news/alzamend-neuro-issues-300-000-shares-conversion-series-b-preferred/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-09-25" section: "Financings" tickers: "NASDAQ:ALZN" source: "https://www.sec.gov/Archives/edgar/data/1677077/000121465925014200/w9252538k.htm" summary: "Between September 17 and September 25, 2025, 696 shares of Series B Convertible Preferred Stock converted into common stock. Alzamend had 3,439,861 common" --- By the aibio.space news desk. Sources - [Alzamend Neuro, Inc. Form 8-K filed September 25, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1677077/000121465925014200/w9252538k.htm) [ALZN](https://aibio.space/companies/alzamend-neuro/) 2025-09-25 # Alzamend Neuro issues 300,000 shares on conversion of Series B preferred stock Tickers [ALZN](https://aibio.space/companies/alzamend-neuro/) Between September 17 and September 25, 2025, 696 shares of Series B Convertible Preferred Stock converted into common stock. Alzamend had 3,439,861 common shares outstanding as of September 25, 2025. ## Key facts - **Company**: Alzamend Neuro, Inc. (NASDAQ: ALZN) - **News type**: Financings - **Primary source**: [Alzamend Neuro, Inc. Form 8-K filed September 25, 2025 (SEC EDGAR)](https://www.sec.gov/Archives/edgar/data/1677077/000121465925014200/w9252538k.htm) *The lower Manhattan skyline. CC0, via rawpixel. The picture shows the field, not the companies named.* Alzamend Neuro, Inc. (Nasdaq: [ALZN](https://aibio.space/companies/alzamend-neuro/)) issued 300,000 shares of common stock between September 17, 2025 and September 25, 2025 on the conversion of 696 shares of Series B Convertible Preferred Stock. The company reported the issuances in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1677077/000121465925014200/w9252538k.htm) filed September 25, 2025. After the issuances, it had 3,439,861 shares of common stock outstanding as of that date. ## What the filing says The filing is made under Item 3.02, the section of Form 8-K that covers unregistered sales of equity securities. It says Alzamend issued an aggregate of 300,000 shares of common stock, par value $0.0001 per share, upon conversion of an aggregate of 696 shares of Series B Convertible Preferred Stock. The conversions took place between September 17, 2025 and September 25, 2025. A conversion of this kind exchanges preferred stock for common shares. The common shares were issued in reliance on the exemption from registration in Section 4(a)(2) of the Securities Act. The shares were not registered with the Securities and Exchange Commission in these issuances. As of September 25, 2025, the company had 3,439,861 shares of common stock outstanding. Executive Vice President and General Counsel Henry Nisser signed the 8-K on behalf of the company on September 25, 2025. ## About the company Alzamend describes itself in its annual report on Form 10-K, filed July 22, 2025, as a clinical-stage biopharmaceutical company. It focuses on developing products for Alzheimer's disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. The report says the company has two product candidates. The first, AL001, is a patented ionic cocrystal that delivers a combination of lithium, salicylate and proline. The company holds three royalty-bearing exclusive worldwide licenses for it from the University of South Florida Research Foundation, Inc. The annual report calls AL001 the company's lead product, licensed and in clinical development in humans. The second, ALZN002, uses a patented method with a mutant peptide sensitized cell as a cell-based therapeutic vaccine. The company says the approach seeks to restore the ability of a patient's immune system to combat Alzheimer's. It holds a royalty-bearing exclusive worldwide license for ALZN002 from the same licensor. ## Financial condition The independent auditor's report in the annual report covers the fiscal years ended April 30, 2025 and 2024. It carries a going concern paragraph. A going concern warning means the auditor has substantial doubt about whether a company can keep operating for the next year without new money. The auditor says the company has experienced recurring losses from operations and negative cash flows from operations, and that it depends on additional financing to fund current and future operations. Those matters, the auditor says, raise substantial doubt about the company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of that uncertainty. ## People and companies named in the filing Henry Nisser signed the 8-K as Executive Vice President and General Counsel. The annual report was signed by Chief Executive Officer Stephan Jackman and Chief Financial Officer David J. Katzoff. William B. Horne signed it as Chairman of the Board, and Milton C. Ault III signed as Vice Chairman of the Board. The University of South Florida Research Foundation, Inc. is the licensor of both product candidates. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ALZN Alzamend Neuro, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/alzamend-neuro-issues-300-000-shares-conversion-series-b-preferred/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alzamend Neuro issues 300,000 shares on conversion of Series B preferred stock", 2025-09-25, https://aibio.space/news/alzamend-neuro-issues-300-000-shares-conversion-series-b-preferred/